Abstract

Over the last decade, research to improve success rates in reproductive medicine has focused predominantly on the understanding and optimization of embryo quality. However, the emergence of personalized medicine in ovulation induction and embryology has shifted the focus to assessing the individual status of the endometrium. The endometrium is considered receptive during an individually defined period, the window of implantation (WOI), when the mother permits a blastocyst to attach and implant. This individual receptivity status can now be objectively diagnosed using the endometrial receptivity array (ERA) developed in 2011. The ERA, together with a computational algorithm, detects the unique transcriptional signature of endometrial receptivity by analyzing 238 differentially expressed genes and reliably predicting the WOI. We and others have illustrated the utility of this personalized diagnostic approach to discriminate between individual physiological variation in endometrial receptivity and unknown endometrial pathology, deemed as causal in recurrent implantation failure (RIF). An international randomized controlled trial (“The ERA as a diagnostic guide for personalized embryo transfer,” ClinicalTrials.gov Identifier: NCT01954758) is underway to determine the clinical value of this endometrial diagnostic intervention in the work-up for reproductive care. In this review, we analyse the current clinical practice in the diagnosis of the endometrial factor together with new avenues of research.

Zusammenfassung

Introduction

Successful implantation of the embryo in the maternal endometrium is the result of a perfect synchrony between a viable blastocyst, the receptive endometrium, and appropriate communication between them [1]. The most investigated element in the implantation triad is the embryo, which seeks to adhere to the endometrial epithelium and invade the decidualized stroma, initiating trophoblast invasion and placentation. Indeed, the understanding of human pre-implantation development is critical (for review see [2]), as are the soluble ligands produced and received by their receptors to mediate this fundamental process (for review see [3]). However, research to develop an understanding of the endometrial component of implantation has been largely neglected.

The maternal endometrium is receptive to an embryo only during the specific period of time in the menstrual cycle known as the window of implantation (WOI). Classically, this period is considered as occurring 8 to 10 days after ovulation and lasting 2 or 3 days, during which time a functional and transient ovarian steroid-dependent status is acquired to enable the blastocyst to implant. This classical definition was established on the grounds of a relevant clinical study [4] but without basic research supporting it. In this important contribution, published by Wilcox et al. in 1999 [4], the day of ovulation was defined on the basis of changes in urinary excretion of the estradiol metabolite estrone 3-glucuronide and the progesterone metabolite pregnanediol 3-glucuronide, which were measured by radioimmunoassay. The authors developed an algorithm to identify the day of ovulation based on the ratio of these urinary hormone metabolites, and claimed the test was similar to measurement of the luteinizing hormone (LH) peak [4]. However, 26 years later, the method proposed by these authors to identify ovulation has not been clinically adopted. Further, we now recognize limitations of the use of LH measurements in urine or even in blood to predict ovulation [5]. Nevertheless, the clinical community has since assumed that the endometrium in all patients becomes receptive during the indicated time frame (8 to 10 days after ovulation), regardless of individual characteristics or hormonal treatments received (i.e., natural cycles or controlled ovarian stimulation).

Human Endometrial Receptivity

To date no single molecular or histological biomarker has been identified to objectively and reliably diagnose endometrial receptivity. In the absence of such a diagnosis, the endometrium has been supported by progesterone or human chorionic gonadotropin (hCG) as the only “endometrial treatment” in patients undergoing assisted reproductive techniques (ART). Accordingly, embryo transfer (ET) has been guided only by the quality and developmental stage of the embryo and the thickness of the endometrial layer. However, we have demonstrated that in 25% of cases repeated implantation failure is attributable to endometrial origin [6], which is consistent with the clinical relevance of endometrial receptivity in successful pregnancy [7]. In 1950 Noyes et al. histologically defined the endometrial dating criteria for evaluating the endometrium [8]. However, multiple randomized [9,10] and prospective studies [11–17] questioned the accuracy and reproducibility of the Noyes method to diagnose endometrial receptivity or fertility status. Subsequent research has focused on discovering biochemical markers to assess endometrial status. Although myriad molecular mediators, including growth factors, cytokines, chemokines, lipids, and adhesion molecules, have been identified in the endometrium [1,7], so far, none of these molecules has been established as an endometrial biomarker in clinical practice [18].

Developments in molecular biology techniques, along with global transcriptomic analyses, have enabled the investigation of the genomics of human endometrial development [19]. Transcriptomic analyses identify actively expressed genes at the mRNA level at any given time [20]. Human endometrial transcriptomic analyses reveal that differential gene expression patterns exist during different phases of the menstrual cycle [21,22], including during the receptive phase [19,23]. Further, differential transcriptomic profiles have been uncovered in patients with repetitive implantation failure [24–26] as well as endometrial pathologies such as endometriosis or endometrial cancer [27,28], and gene expression patterns have been defined during controlled ovarian stimulation (COS) and hormonal replacement therapy (HRT) cycles [29,30]. These efforts enabled the discovery of the unique genomic signature of endometrial receptivity that became the basis of the endometrial receptivity array (ERA) [31]. This assay diagnoses the molecular status of the receptive endometrium according to its transcriptomic signature, regardless of its histological appearance [31].

Endometrial Receptivity Array

The ERA is a novel diagnostic method clinically available worldwide that classifies the endometrium as receptive, pre-receptive, or post-receptive [6]. The test requires a small biopsy of endometrial tissue taken during scheduled treatment at either 7 days after the luteinizing hormone peak (LH+) 7) in a natural cycle, or at the end of 5 days of progesterone administration after estrogen priming in a hormonal replacement therapy cycle (P+5). RNA extracted from the tissue is applied to a microarray to determine the transcriptomic profile of 238 genes. This transcriptomic profile, when coupled to a computational predictor, objectively identifies whether this endometrium is receptive, pre-receptive or post-receptive by clustering analysis against sample training sets [6,31]. The 238 genes analyzed by ERA were chosen according to the expression data of 14 previous papers by our group searching for the transcriptomic signature of endometrial receptivity in natural cycles, COS, HRT and even in patients with intrauterine device (IUD) (for review see [19]). Although these genes were selected by t-test with an absolute fold change > 3 and a false discovery rate < 0.05, the clinical validation was done with a training set in real patients [31]. Importantly, the result obtained by ERA is independent of the histological appearance of the endometrium, and has been demonstrated to be more accurate than histological dating [32] and completely reproducible even with up to 40 months between samples [32]. This finding is consistent with the idea that the receptivity status remains the same within an individual woman throughout her lifetime, but that different hormonal treatments and states such as pregnancy may change the endometrium since it is a hormonally regulated organ.

Analysis of over 6000 ERA results, performed by our group, indicates that, in approximately 30% of patients, the endometrial biopsy is classified as non-receptive. In these instances, the predictor describes whether the tissue is pre-receptive (85.0%) or post-
Based on these findings, the algorithm then recommends the timing of progesterone treatment for the individual patient to find her personalized WOI, thereby obtaining an optimal chance of successful implantation through personalized embryo transfer (pET) (Fig. 1).

**Personalized Embryo Transfer**

The clinical application of the ERA has been studied in a prospective, interventional, multicenter, clinical trial in 85 patients with recurrent implantation failure (RIF) versus 25 controls undergoing IVF for the first time [6]. The endometrial biopsy was classified as receptive in 74.1% of patients with RIF; when embryo transfer was performed according to the timing indicated by ERA diagnosis, patients achieved a 33.9% implantation rate and a 51.7% pregnancy rate. However, displacement of the WOI was observed in one out of four patients with RIF as diagnosed by ERA [6]. In these 26.3% of patients, when embryo transfer was performed according to ERA-diagnosed timing of the WOI, pregnancy and implantation rates rose to the level of normally receptive controls, in this initial study 7 patients underwent pET.

Similarly, in a pilot study of 17 patients undergoing oocyte donation who had experienced failed implantations with routine embryo transfer, the implantation rate was increased from 12.9 to 34.5% and the pregnancy rate from 23.5 to 52.9% when pET was performed following ERA diagnosis [33]. All 17 patients were initially diagnosed with a displaced WOI, whereby the endometrium biopsy was classified pre-receptive in 16 patients and post-receptive in one patient [33]. The value of the diagnosis of endometrial receptivity during the routine infertility work-up of patients undergoing assisted reproductive technology is currently being explored in an international, multicenter, prospective, randomized, interventional and controlled study – “The ERA as a diagnostic guide for personalized embryo transfer” – comparing fresh embryo transfer versus elective delayed embryo transfer or pET (Clinical trails.gov, Identifier: NCT01954758).

**MicroRNAs: New Molecules Advancing Our Reproductive Knowledge**

Despite the wealth of information uncovered in recent years, technologies continue evolving to discover all transcripts across the transcriptome. In 2014, Hu et al. reported the first global gene expression profile of the human endometrium using next-generation, high-throughput RNA sequencing (RNA-seq) [34]. This RNA-seq-based transcriptome comparison of pre-receptive and receptive human endometrium revealed a total of 2372 differentially expressed genes, including metallothionein family mem-

---

Fig. 1 Clinical algorithm for personalized embryo transfer (pET), including the percentage probability (unpublished data provided by C. Simon).
MiRNAs are small, non-coding RNA sequences of 18 to 25 nucleotides that regulate gene expression post-transcriptionally [40]. These molecules do not encode proteins; instead, miRNAs target mRNAs through complementary base pairing to the 3’-untranslated region for degradation or repression, thereby functioning as gene silencers [41]. Based on the degree of sequence homology, one miRNA can potentially target a broad range of genes and one gene can be regulated by several miRNAs [40]. Initially, long precursors (pri-miRNAs) are transcribed and processed to shorter precursors (pre-miRNAs) in the nucleus [37]; these precursors are exported into the cytoplasm and incorporated into the RNA-induced silencing complex (RISC) to bind an mRNA target. miRNAs can potentially target a broad range of genes and one gene can be regulated by several miRNAs [40].

As has been found for mRNAs, miRNAs are differentially expressed in the endometrium across the menstrual cycle [43]. Further, the endometrial epithelium releases miRNAs that are secreted into the endometrial fluid [43]. Profiling of miRNA and mRNA transcripts in human endometrium suggests that the hormonal regulation of miRNAs leads to a suppression of cell proliferation by down-regulating the expression of some cell cycle genes in the endometrial epithelium during the secretory phase [44]. By isolating endometrial epithelial cells from endometrial biopsies of 14 fertile women in the late-proliferative and mid-secretory phases, Kuokkanen et al. identified miRNA-29B, miRNA-29C, miRNA-30B, miRNA-30d, miRNA-31, miRNA-193A-3P, miRNA-203, miRNA-204, miRNA-200C, miRNA-210, miRNA-582-5p, and miRNA-345 as significantly increased in the secretory endometrium [43]. Furthermore, it has been suggested that miRNAs can be secreted by the human embryo [48]; hsa-miR-191, hsa-miR-372, and hsa-miR-645 are differentially expressed according to the fertilization method, chromosomal status, and pregnancy outcome. Together, these findings reinforce the concept of maternal-embryonic cross-talk that uses many different languages, with miRNAs as one of them.

**Conclusion**

The receptivity status of the endometrium can now be diagnosed reliably by the ERA test, an objective molecular tool based on the transcriptomic signature of human endometrial receptivity, to identify the WOI. The ERA can guide and improve our clinical practice by introducing and enabling a personalized diagnosis of the WOI and, accordingly, a personalized embryo transfer. In the near future, the challenge will be to identify biomarkers of endometrial receptivity that could be assessed by non-invasive methods. MiRNAs may be interesting candidate molecules to consider, particularly with the potential role of maternal endometrial miRNAs as transcriptomic modifiers of the preimplantation embryo.
Conflict of Interest

CS is inventor of the ERA patent and holds shares in Igenomix, the company commercializing the ERA test. MR & FV are employees of Igenomix.

References

5 Direito A, Bailly S, Mariani A et al. The genomics of the human endometrium, is taken up by the pre-implantation embryo and might modify its transcriptome. Development 2015; 142: 3210
17 Matsuzaki S. DNA microarray analysis in endometriosis for development of more effective targeted therapies. Front Biosci (Elite Ed) 2011; 3: 1139–1153